First and only PARP inhibitor to improve invasive disease-free survival in patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated
